港股異動 | 盈健醫療(1419.HK)高開16.2% 預期中期純利增長433%
格隆匯2月14日丨盈健醫療(1419.HK)高開16.2%,報1.65港元,總市值6.19億港元。該公司2月11日盤後公佈,公司擁有人應占溢利預期由截至2020年12月31日止六個月的約1690萬港元增加至截至2021年12月31日止6個月的約9000萬港元,較2020年同期增幅約433%。主要由於:(i)全科醫療服務收入增加,此乃由於全科醫療服務範疇如預防、檢測、疫苗接種及外展服務的擴展,當中包括2019冠狀病毒病相關的服務;(ii)毛利增加,此乃由於收益增加以及服務範疇多樣化配合不同成本結構導致全科醫療服務的毛利率上升;(iii)保就業計劃的政府資助減少導致其他收入及收益減少的抵銷;及(iv)所得税開支增加的抵銷所致。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.